Results 161 to 170 of about 28,600 (213)

Real-world antipsychotic prescribing pathways and treatment modifications in schizophrenia spectrum disorders: evidence from the United Arab Emirates. [PDF]

Front Pharmacol
Bokhari SA, Elnoor M, Javaid SF, Alnor MA.   +3 more
europepmc   +1 more source

Neuropsychiatric-pharmacologic synergy: interaction between psychiatric polypharmacy and cancer treatment-related neurotoxicity. [PDF]

Oxf Med Case Reports
Woytowitz SP, Manchee C.
europepmc   +1 more source

Case Report: Early onset pulmonary embolism following antipsychotic polypharmacy in an acute psychiatric setting. [PDF]

Front Psychiatry
Fesenmeier S, Aigner M, Filipovits D, Höflich A.   +3 more
europepmc   +1 more source

Safety, Tolerability, and Pharmacokinetics of Subcutaneous Extended-Release Injectable Olanzapine in Patients with Schizophrenia and Schizoaffective Disorder. [PDF]

Clin Drug Investig
Cherniakov I, Wagner AM, Eshet R, Tiver R, Bibi D, Perlstein I, Kalmanczhelyi A, Sharon N, Cohen G, Ferderber K, Roberts J, Elgart A, Gutman D, Rabinovich-Guilatt L.   +13 more
europepmc   +1 more source

Incidence and clinical characteristics of zolbetuximab-induced nausea and vomiting in CLDN18.2-positive unresectable advanced or recurrent gastric cancer: a retrospective study. [PDF]

J Pharm Health Care Sci
Ando Y, Banno H, Yamaguchi S, Ban A, Katsuragawa K, Sakurai R, Sato Y, Nakamura S, Sasaki T, Inoue H, Kumazawa S, Koyama T, Harada S, Mishima E, Matsuoka H, Yamada S, Miyazaki M.   +16 more
europepmc   +1 more source

Second-Generation Antipsychotics for Depression in Serious Illness: A First-Line Augmentation Strategy. [PDF]

J Pain Symptom Manage
Robbins-Welty G, Pattillo M, Chammas D, Sadowska K, McDermott CL, Ufere N, Webb JA, Shalev D.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Olanzapine

Clinical Pharmacokinetics, 2012
Olanzapine is an atypical antipsychotic agent of the thienobenzodiazepine class. Olanzapine blocks multiple neurotransmitter receptors, including dopaminergic (D 1 , D 2 , D 3 , and D 4
Charles M Beasley, Richard F Bergstrom, Beasley Charles M   +2 more
exaly   +6 more sources

Olanzapine Abuse

Substance Abuse, 2013
Olanzapine is a thienobenzodiazepine that blocks especially the serontonin (5-hydroxytryptamine [5-HT]) 5-HT2A and the dopamine D2 receptors as well as muscarinic (M1), histamine (H1), 5-HT2C, 5-HT3 to 5-HT6, adrenergic (α l ), and D4 receptors.
Sakarya Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü, Erol, Atila, Erol, Atila   +2 more
openaire   +2 more sources

Olanzapine and Pregnancy

Pharmacopsychiatry, 2002
This report focuses on the case of a pregnant woman with a bad obstetric history who developed psychosis at the 23 rd week of gestation. She was treated with olanzapine from the 24th week until 10 days prior to delivery. No adverse events occurred during pregnancy or delivery. The Apgar score was 8/10 at one minute and 9/10 at 5 minutes.
D N, Mendhekar, L, War, J B, Sharma, R C, Jiloha   +3 more
openaire   +2 more sources

Olanzapine

Clinical Pharmacokinetics, 1999
Multicentre trials in patients with schizophrenia confirm that olanzapine is a novel antipsychotic agent with broad efficacy, eliciting a response in both the positive and negative symptoms of schizophrenia. Compared with traditional antipsychotic agents, olanzapine causes a lower incidence of extrapyramidal symptoms and minimal perturbation of ...
J T, Callaghan, R F, Bergstrom, L R, Ptak, C M, Beasley   +3 more
openaire   +3 more sources